The Humalog 100IU/mL (Insulin Lispro) Refill Cartridge, 3mL, represents a pivotal innovation in diabetes management, offering individuals with diabetes a rapid-acting insulin analog designed to mirror the body's natural mealtime insulin response. Engineered for precision, reliability, and user convenience, this refill cartridge is specifically developed for use with compatible insulin pen delivery systems, facilitating accurate dosing and enhancing overall treatment adherence. As a cornerstone of physiologic insulin regimens for both Type 1 and Type 2 diabetes, Humalog plays a critical role in controlling postprandial blood glucose excursions, thereby helping to reduce the risk of long-term complications.
Core Mechanism of Action & Pharmacological Profile
Humalog (insulin lispro) is a rapid-acting insulin analog distinguished by its reversed amino acid sequence (lysine at position B28 and proline at position B29) compared to regular human insulin. This molecular modification facilitates faster absorption, an earlier onset of action, and a shorter duration of activity. When administered subcutaneously, Humalog begins to lower blood glucose levels within approximately 15 minutes, peaks in activity between 30 minutes to 2.5 hours, and maintains its effect for 3 to 5 hours. This pharmacokinetic profile makes it ideally suited for mealtime (prandial) dosing, allowing patients to inject immediately before or even after a meal—a significant flexibility advantage over regular human insulin, which typically requires injection 30-60 minutes prior to eating.
The primary action of Humalog, like all insulins, is to facilitate the cellular uptake of glucose, particularly in muscle and adipose tissue, while simultaneously inhibiting hepatic glucose production. By controlling the sharp rise in blood sugar following carbohydrate ingestion, Humalog helps maintain glycemic stability throughout the day. It is typically used in conjunction with a long-acting (basal) insulin to provide a full 24-hour insulin coverage regimen, closely simulating a healthy pancreas's function.
Primary Indications & Therapeutic Use Cases
Humalog 100IU/mL Cartridge is indicated for the management of:
Type 1 Diabetes Mellitus: As part of an intensive insulin therapy regimen, providing the essential prandial insulin component alongside basal insulin.
Type 2 Diabetes Mellitus: For patients who require mealtime insulin to achieve optimal glycemic control despite the use of oral antidiabetic agents, non-insulin injectables, or basal insulin.
Continuous Subcutaneous Insulin Infusion (CSII): Via an insulin pump. The 3mL refill cartridge is designed for specific pump models, offering a sterile, precise, and convenient reservoir for pump therapy.
Key Features & Patient-Centric Benefits
Rapid Onset & Meal Flexibility: The fast-acting nature of insulin lispro allows for injection at mealtime, accommodating unpredictable eating schedules and varying carbohydrate intake. This can significantly improve quality of life and reduce the anxiety associated with strict pre-meal timing.
Improved Postprandial Glucose Control: By quickly addressing the glucose spike from meals, Humalog contributes directly to better overall HbA1c management and may reduce the risk of hyperglycemia-related complications.
Reduced Hypoglycemia Risk (vs. Regular Insulin): Due to its shorter duration of action, Humalog is associated with a lower incidence of late postprandial and between-meal hypoglycemic events compared to regular human insulin when dosed appropriately.
Precision Dosing with Pen Devices: The 3mL refill cartridge is engineered for use with durable, reusable insulin pens (e.g., specific Lilly insulin pens). These devices allow for dose adjustments in 0.5 or 1-unit increments, promoting accuracy—especially crucial for low-dose requirements—and reducing dosing errors.
Convenience & Portability: Pen systems are discreet, easy to use, and eliminate the need to carry vials and syringes. The cartridge refill system is often more economical and environmentally friendly than disposable prefilled pens.
Consistency & Purity: Manufactured using recombinant DNA technology, Humalog provides a consistent, high-purity insulin product free from animal-source contaminants, ensuring reliable performance with every dose.
Administration & Dosage Guidelines
Dosage is highly individualized and must be determined by a healthcare professional based on metabolic needs, blood glucose monitoring results, and glycemic control goals. It is typically administered subcutaneously in the abdominal wall, thigh, buttocks, or upper arm. Rotation of injection sites within the same region is recommended to prevent lipodystrophy.
For Pen Use: The cartridge is inserted into the compatible insulin pen according to the manufacturer's instructions. A new, sterile pen needle must be attached for each injection. After priming the pen to ensure an insulin flow, the patient dials the prescribed dose and administers the injection.
Timing: Administer within 15 minutes before a meal or immediately after a meal.
Never share an insulin pen or cartridge between patients, even with needle changes, due to the risk of bloodborne pathogen transmission.
Critical Safety Information, Warnings, & Side Effects
Hypoglycemia: The most common and potentially serious adverse effect. Symptoms include sweating, dizziness, tremor, palpitations, hunger, confusion, and seizures. Risk factors include delayed meals, increased physical activity, overdose, and renal/hepatic impairment. Patients must be educated on recognition, treatment (with fast-acting carbohydrates), and prevention.
Hypersensitivity & Allergic Reactions: Severe, life-threatening anaphylaxis is rare but possible. Localized reactions (redness, itching, swelling at the injection site) may occur and often resolve with continued use.
Hypokalemia: Insulin, including Humalog, causes a shift of potassium into cells, potentially leading to low blood potassium levels, which can be dangerous for cardiac function.
Weight Gain: Can occur with improved metabolic control and calorie retention.
Lipodystrophy: Can manifest as lipohypertrophy (thickening of fatty tissue) or lipoatrophy (thinning of fatty tissue) at injection sites. Rotating injection sites minimizes this risk.
Fluid Retention & Heart Failure: Particularly with intensive insulin therapy in patients prone to heart failure.
Contraindications: During episodes of hypoglycemia and in patients hypersensitive to insulin lispro or any excipients in the formulation.
Storage, Handling, & Stability
Unopened (Refrigerated): Store unused 3mL cartridges at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep away from the cooling element. Protect from light.
In-Use (Pen/Device): Once a cartridge is placed in a pen device for use, it should NOT be refrigerated. It can be kept at room temperature (below 30°C or 86°F) for up to 28 days. The pen in use must be stored without a needle attached.
Do not use if the insulin appears cloudy, discolored, or contains particles. Humalog should be a clear, colorless solution.
Conclusion: A Trusted Partner in Diabetes Management
The Humalog 100IU/mL Refill Cartridge (3mL) is more than just insulin; it is a sophisticated therapeutic tool designed to empower individuals with diabetes. By offering rapid, predictable action paired with the convenience and accuracy of modern pen delivery systems, it supports a proactive approach to glycemic control. Its role in managing postprandial glucose is integral to achieving long-term HbA1c targets and promoting better health outcomes.
On all orders is set at $25.00
Protected by Bitcoin
On all huge orders